Life Sciences & MOB See Resilient Investment Amidst Market Headwinds
By RadCRE Research · · Industry Insights
Despite broader CRE challenges, life sciences and medical office building (MOB) sectors are demonstrating robust investment demand, with MOB transaction volume reaching $21.5 billion in 2023.
Resilient Demand for Recession-Resistant Healthcare Assets
The commercial real estate landscape, characterized by elevated interest rates and tighter lending conditions, has presented significant challenges across many property sectors. However, two specialized asset classes—life sciences and medical office buildings (MOBs)—continue to demonstrate remarkable resilience and robust investor demand. Their defensive characteristics, driven by non-discretionary healthcare spending and long-term demographic tailwinds, position them favorably against broader market volatilities.
Life Sciences: Innovation Drives Sustained Growth
Despite a moderation from the frenzied investment pace of 2021-2022, the life sciences sector remains a magnet for institutional capital. Key hubs such as Boston-Cambridge, San Francisco Bay Area, and San Diego continue to attract significant investment, fueled by venture capital funding for biotech and pharmaceutical R&D. According to JLL's 2024 Life Sciences Outlook, while lab vacancy rates have trended upwards in some markets, substantial pre-leased developments indicate a flight to quality and innovation. For instance, BioMed Realty, a Blackstone portfolio company, recently broke ground on its 370,000 square-foot Gateway of Pacific project in South San Francisco, demonstrating continued confidence in prime locations.
Investment volume for life sciences properties, though down from peak levels, stabilized in late 2023 and early 2024. Cushman & Wakefield reported that average asking rents for lab space in major clusters remain strong, often commanding premiums over traditional office space. Cap rates for Class A life sciences assets, particularly in core markets, have compressed relative to other commercial sectors, indicating sustained buyer interest. While some speculative development has paused, build-to-suit projects for established biopharmaceutical firms continue apace, underscoring fundamental demand.
Medical Office Buildings: A Defensive Investment Proposition
Medical office buildings have long been recognized for their stability, offering long lease terms, credit-worthy tenants (e.g., major hospital systems), and predictable cash flows. This stability has made MOBs particularly attractive in the current economic climate. According to a recent report by Revista and HREI, total MOB transaction volume reached an impressive $21.5 billion in 2023, slightly down from 2022's all-time high but still significantly above pre-pandemic averages. This sustained activity showcases the asset class's defensive appeal.
Key deals highlight this ongoing demand. For example, Physicians Realty Trust (NYSE: DOC) was acquired by Healthpeak Properties (NYSE: PEAK) in a $21.0 billion all-stock transaction recently, creating one of the largest REITs focused on healthcare real estate. This mega-merger underscores the strategic aggregation of quality MOB portfolios. Furthermore, average cap rates for MOBs have demonstrated relatively modest increases compared to other asset classes, typically ranging from 5.5% to 6.8% for stabilized, institutionally owned properties, depending on location and tenant quality.
The decentralization of healthcare, driven by technological advancements and patient preference for convenient outpatient services, continues to fuel MOB development and investment. Urban and suburban medical corridors, particularly in growth markets like Dallas, Phoenix, and Nashville, are experiencing strong demand for new and modernized MOB facilities.
RadCRE's Role in Healthcare Real Estate
At RadCRE, we recognize the distinct advantages and complexities of investing in life sciences and medical office real estate. Our team offers specialized advisory and investment banking services to clients looking to acquire, divest, or finance these high-performing assets. Leveraging our deep sector knowledge and extensive network, we assist investors in navigating the unique underwriting requirements, tenant specificities, and capital stack optimizations necessary to succeed in this specialized domain, from ground-up development financing for lab facilities to portfolio sales of stabilized MOBs. Our analytical approach, powered by RadCRE.ai, allows for precise valuation and risk assessment, ensuring optimal outcomes for our clients.
Tags: life sciences real estate, medical office building investment, CRE investment demand, healthcare real estate, RadCRE advisory
Sources: JLL, Cushman & Wakefield, Revista, HREI, CoStar, GlobeSt, Blackstone, Healthpeak Properties